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Abstract 
Itraconazole (ITZ) is a well-known, FDA-approved antifungal drug that is also in clinical trials 
for its anticancer activity. ITZ exerts its anticancer activity through several disparate targets and 
pathways. ITZ inhibits angiogenesis by hampering the functioning of the vascular endothelial 
growth receptor 2 (VEGFR2) and by indirectly inhibiting mTOR signaling. Furthermore, ITZ 
directly inhibits the growth of several types of tumor cells by antagonizing Hedgehog signaling. 
Recently, we reported that ITZ also has broad-spectrum antiviral activity against enteroviruses, 
cardioviruses and hepatitis C virus, independent of established ITZ-activities but instead via a 
novel target, oxysterol-binding protein (OSBP), a cellular lipid shuttling protein. In this study, we 
analyzed which structural features of ITZ are important for the OSBP-mediated antiviral activity. 
The backbone structure, consisting of five rings, and the sec-butyl chain are important for 
antiviral activity, whereas the triazole moiety, which is critical for antifungal activity, is not. The 
features required for OSBP-mediated antiviral activity of ITZ overlap mostly with published 
features required for inhibition of VEGFR2 trafficking, but not Hh signaling. Furthermore, we 
use in silico studies to explore how ITZ could bind to OSBP. Our data show that several 
pharmacological activities of ITZ can be uncoupled, which is a critical step in the development of 
ITZ-based antiviral compounds with greater specificity and reduced off-target effects. 
 
Keywords: Itraconazole; Encephalomyocarditis virus; Cardiovirus; Enterovirus; Molecular 
modeling 
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Introduction 
Enteroviruses form a large group of viruses within the Picornaviridae family of positive-sense 
single stranded RNA (+RNA) viruses. The enteroviruses include many important human 
pathogens, including poliovirus (causative agent of poliomyelitis), coxsackieviruses and 
echoviruses (causative agents of encephalitis, meningitis, and hand, foot, and mouth disease) and 
rhinoviruses (causative agents of common cold, but also have a role in exacerbations of asthma 
and chronic obstructive pulmonary disease) (Tapparel et al., 2013). Vaccines are available against 
poliovirus, and an enterovirus-A71 vaccine has recently been approved in China. However, 
vaccination is not a feasible general strategy to prevent infections with the large amount (>250) 
of enterovirus (sero)types. No antiviral therapies are approved at the moment, restricting 
treatment of infections to supportive care. Therefore, antiviral drugs that target a broad spectrum 
of enteroviruses are urgently needed. Such drugs could either directly target viral proteins or act 
through essential host factors. Repurposing of approved drugs or compounds that have passed 
clinical trials, for which detailed information on safety and pharmacology is available, is an 
emerging alternative to the time consuming and costly de novo development of antiviral drugs. 
Recently, ITZ was identified in several drug-repurposing screens as a novel broad-spectrum anti-
enteroviral agent that affects genome replication (Gao et al., 2015; Shim et al., 2016a; Strating et 
al., 2015). Besides enteroviruses, ITZ also inhibits picornaviruses of the Cardiovirus genus and 
hepatitis C virus, a +RNA virus belonging to the Flaviviridae family.  
ITZ (Sporanox®) is an FDA-approved drug that is clinically used for the treatment of fungal 
infections. ITZ acts by inhibiting the activity of the fungal enzyme CYP51 (lanosterol 14α-
demethylase), which catalyzes an essential step in the biosynthesis of cell membrane sterols, thus 
impairing fungal cell membrane integrity (Lestner and Hope, 2013). ITZ also inhibits the human 
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CYP51 isoform, although ~10-fold less potently than fungal CYP51, and the related drug 
metabolizing enzyme CYP3A4 (Lamb et al., 1999; Trosken et al., 2006). In drug-repurposing 
screens, ITZ was found to exert antitumor activity via a number of targets. ITZ directly inhibits 
cancer cells that depend on the Hedgehog (Hh) pathway by antagonizing Hh signaling (Kim et al., 
2010). Besides, ITZ possesses potent antiangiogenic activity by indirectly inhibiting mTOR and 
vascular endothelial growth factor receptor 2 (VEGFR2) functioning. ITZ inhibits mTOR by 
targeting the mitochondrial voltage-dependent anion channel 1 (VDAC1) and the lysosomal 
cholesterol-binding protein Niemann-Pick disease type C1 (NPC1) (Head et al., 2015; Head et al., 
2017; Trinh et al., 2017; Xu et al., 2010). ITZ interferes with the signaling activity of VEGFR2 
by altering its trafficking and glycosylation (Aftab et al., 2011; Nacev et al., 2011), but the 
molecular target mediating this activity remains to be identified. So far, ITZ has displayed 
efficacy in several phase II clinical trials with patients with a number of different cancer types 
(Antonarakis et al., 2013; Kim et al., 2014; Rudin et al., 2013). 
We previously reported that ITZ has antiviral activity (Strating et al., 2015). Since compounds 
that pharmacologically inhibit the other targets of ITZ do not interfere with virus replication, we 
concluded that the established activities of ITZ are likely unrelated to the antiviral activity. 
Instead, we identified oxysterol-binding protein (OSBP) as a novel target of ITZ through which 
the antiviral activity is exerted (Strating et al., 2015). We showed that ITZ directly binds OSBP 
and that other OSBP inhibitors (e.g. OSW-1) also have antiviral activity (Albulescu et al., 2015; 
Strating et al., 2015). Depletion of OSBP sensitized virus replication to ITZ whereas OSBP 
overexpression counteracted virus inhibition by ITZ, thus further strengthening our conclusion 
that ITZ exerts its antiviral activity via OSBP (Strating et al., 2015). 
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OSBP shuttles lipids at membrane contact sites (MCSs), i.e. sites where two organelles come in 
very close proximity, between the endoplasmic reticulum (ER) and the trans-Golgi apparatus 
(Mesmin et al., 2013). OSBP bridges the ER-Golgi MCS by simultaneously binding these two 
organelles. OSBP connects to the ER via an interaction of its FFAT-motif with the ER integral 
membrane proteins VAP-A or VAP-B. At the other side of the MCS, the PH-domain of OSBP 
binds the small GTPase Arf1 and phosphatidylinositol 4-phosphate [PI(4)P] lipids to connect 
OSBP to the trans-Golgi. The C-terminal OSBP-related domain (ORD) of OSBP can 
accommodate the lipids cholesterol and PI(4)P in its lipophilic pocket. The ORD mediates 
shuttling of cholesterol from the ER to the Golgi, which occurs against the concentration gradient. 
A concurrent shuttling of PI(4)P from the trans-Golgi to the ER, where PI(4)P is hydrolyzed by 
the phosphatase Sac1, provides the driving force for cholesterol transport. Because PI(4)P also 
acts as a membrane anchor for OSBP at the trans-Golgi, PI(4)P shuttling allows a negative 
feedback of OSBP localization and, as a result, activity (Mesmin et al., 2013). ITZ inhibits the 
cholesterol and PI(4)P shuttling activities of OSBP both in vitro and in cells. As a result of the 
inhibition of PI(4)P shuttling, ITZ prevents PI(4)P removal from the Golgi, leading to an 
accumulation of both PI(4)P and OSBP at ER-Golgi MCSs (Strating et al., 2015). 
Like all +RNA viruses, picornaviruses rewire the cellular membrane system to generate 
membranous replication platforms, so-called replication organelles (ROs) (for recent reviews, see 
Strating and van Kuppeveld, 2017; van der Schaar et al., 2016). Each group of viruses recruits a 
specific set of host proteins to the ROs through viral non-structural proteins. For example, all 
enteroviruses recruit the Golgi-derived enzyme phosphatidylinositol 4-kinase type III β (PI4KB), 
which converts PI lipids into PI(4)P, leading to an enrichment of PI(4)P at ROs (Hsu et al., 2010; 
van der Schaar et al., 2013). The cardiovirus encephalomyocarditis virus (EMCV) instead relies 
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on a different isoform, namely phosphatidylinositol 4-kinase type III  (PI4KA), to generate 
PI(4)P-rich ROs (Dorobantu et al., 2015). The PI(4)P lipids allowing the recruitment of OSBP 
and drive the shuttling of cholesterol to ROs (Arita et al., 2013; Dorobantu et al., 2015; Roulin et 
al., 2014; Strating et al., 2015). By inhibiting the lipid shuttling activity of OSBP, ITZ hampers 
cholesterol transport to ROs and hence interferes with RO biogenesis and viral genome 
replication (Strating et al., 2015). 
Here, we report a structure-activity relationship study of ITZ in which we aim to establish which 
structural features of ITZ are important for the inhibition of the lipid shuttling activity of OSBP 
and virus replication, which depends on OSBP. To study the antiviral effect of ITZ analogs, we 
used the cardiovirus EMCV as a model virus that is highly sensitive to ITZ (Strating et al., 2015). 
As a read-out for inhibition of OSBP lipid shuttling activity, we used the accumulation of OSBP 
at the Golgi, which is induced by the inhibition of OSBP-mediated PI(4)P shuttling from the 
Golgi (Strating et al., 2015). Furthermore, we performed molecular modeling studies to 
investigate how ITZ may bind to OSBP. We observed that the activity of the analogs towards 
OSBP and virus replication correlate well. Interestingly, there is overlap of antiviral activity of 
most analogs, except for two stereoisomers, with previously reported activity towards VEGFR2, 
but not Hh. Finally, our molecular modeling studies indicate that ITZ occupies the hydrophobic 
tunnel in the ORD which normally accommodates cholesterol and PI(4)P, thus offering a 
potential explanation of its mode of inhibition. Together, this study provides insight into the 
structural features of ITZ that are necessary for its OSBP-mediated antiviral activity, paving the 
way for further development of ITZ-based compounds as antiviral agents with greater specificity 
towards OSBP and fewer side activities (i.e. not targeting other ITZ targets such as CYP51 and 
Hh).  
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Results 
Antiviral activity of ITZ and inhibition of OSBP 
ITZ (Figure 1) consists of a core of five linearly linked rings (dioxolanyl-methoxyphenyl-
piperazinyl-phenyl-triazolone) with substituents on either side of the core. The dioxolane ring 
carries a dichlorophenyl ring and a triazole moiety, the latter of which is essential for the CYP51-
mediated antifungal activity. The triazolone ring on the other end of the core bears a sec-butyl 
chain that is important for the activity of ITZ towards VEGFR2 and Hh (Shi et al., 2011). ITZ 
has three stereogenic centers (2, 4 and 2’) and thus a total of eight possible stereoisomers. To 
investigate the importance of different parts of ITZ for the antiviral activity, we used a small 
library of ITZ stereoisomers and analogs that either lacked major parts of the molecule or that 
had alterations in the triazole or sec-butyl moieties (Chong et al., 2007; Head et al., 2015; Shi et 
al., 2011; Shi et al., 2010). The antiviral activity of ITZ analogs was investigated using 
encephalomyocarditis virus (EMCV), a member of the Cardiovirus genus that, like enteroviruses, 
requires OSBP and is highly sensitive to ITZ (Dorobantu et al., 2015; Strating et al., 2015). HeLa 
cells were infected with a recombinant virus encoding a Renilla luciferase reporter gene (RLuc-
EMCV) (Albulescu et al., 2015), treated with serial dilutions of ITZ analogs, and luciferase 
activity was determined as a quantitative and sensitive readout for virus replication (Figure 2A). 
In parallel, an MTS assay was performed to test for cytotoxicity of the compounds (Figure 2B). 
Technical replicates were performed as biological triplicates and EC50 values were calculated 
(Supplementary Table 1, Figure 2C). As a readout for inhibition of the lipid shuttling activity of 
OSBP, cells transiently expressing EGFP-tagged OSBP were treated with 10 μM of compound, 
fixed and imaged by fluorescence microscopy to assess the accumulation of OSBP at the Golgi 
(Figure 2D). 
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Overall, we considered compounds active when EC50 values were in a similar order of magnitude 
(i.e. less than ten-fold different from ITZ), whereas we considered them inactive when there was 
minimal or no inhibition at the highest concentration tested (indicated as EC50 values >10µM) 
(Tables 1-4, Supplementary Table 1, Figure 2C). In line with our previous conclusion that the 
antiviral activity of ITZ is mediated through OSBP (Strating et al., 2015), we observed a strong 
correlation between activity in the antiviral assay and the OSBP redistribution assay. 
Clinically administered ITZ to treat fungal infections consists of an equimolar mixture of the four 
cis-stereoisomers (2S4R2’S; 2S4R2’R; 2R4S2’S; 2R4S2’S). All eight stereoisomers (compounds 
1a-h) clearly inhibited virus replication without notable acute cytotoxicity and induced a 
perinuclear OSBP accumulation indicative of an inhibition of the lipid shuttling activity of OSBP. 
The individual clinically administered stereoisomers (1a-d) had a similar potency as the clinically 
used ITZ mixture and were slightly more potent (up to ~8.5 fold) than the other stereoisomers 
(1e-h) (Table 1, Figure 2C). The stereoisomers in clinically used ITZ (1a-d) were also previously 
reported to be more active towards VEGFR2 glycosylation (Table 1) (Shi et al., 2011). Despite 
the small differences in potency, it is obvious that all eight stereoisomers are active towards 
OSBP and possess antiviral activity. 
The triazole ring is a key feature for the antifungal effect of ITZ (Odds et al., 2003). To test the 
importance of the triazole ring for antiviral activity, we assayed an analog lacking the triazole 
ring (compound 2), one bearing imidazole instead of triazole (compound 3), and an analog with 
tetrazole (compound 4) in place of triazole (Table 2). All compounds retained antiviral activity 
and induced accumulation of OSBP at the Golgi compartment, without displaying toxicity. These 
data indicate that the triazole moiety is not important for the antiviral activity of ITZ and that it 
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can be removed to reduce side effects caused by inhibition of the human CYP51 or CYP3A4 
enzymes. 
Next, we analyzed a group of analogs with variations in the sec-butyl side chain (Table 3), none 
of which displayed toxicity in the MTS assay. Compound 5, which altogether lacks the sec-butyl 
chain, did not inhibit virus replication or redistribute OSBP to the Golgi. Likewise, compound 6, 
which has the sec-butyl chain substituted with a linear side chain, was inactive towards virus 
replication and OSBP redistribution. In contrast, replacing the sec-butyl chain with a branched 
(compound 7) or a cyclohexane (compound 8) side chain did not affect the activity towards virus 
replication and OSBP accumulation. Together, these data indicate that a bulky, branched side 
chain is important for the OSBP-mediated antiviral activity of ITZ.  
Finally, we tested a set of analogs that lack major parts of the dioxolane or triazolone regions 
(Table 4). Analogs lacking the triazolone region with its sec-butyl side chain (terconazole, 
compound 9, compound 10) did not redistribute OSBP or inhibit virus replication. It should be 
noted that we have previously shown that ketoconazole lacks antiviral activity and does not affect 
OSBP (Strating et al., 2015). Ketoconazole is also a clinically used antifungal drug that is 
virtually identical to compound 10 except that it has an imidazole ring instead of a triazole ring. 
However, since these analogs also lack the essential sec-butyl chain, we cannot discern whether 
this causes the lack of activity or whether the phenyl and triazolone rings in the core structure are 
also important. Compound 11, which encompasses the linker and the triazolone region including 
the sec-butyl chain but lacks the dioxolane region, was also not able to redistribute OSBP and 
showed no antiviral effect. We previously reported that posaconazole, which is structurally 
highly similar to ITZ (it comprises a difluorobenzyl ring instead of a dichlorobenzyl ring, the 
dioxolane ring is substituted to an oxolane, and an elongated branched side chain), is also capable 
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of inhibiting virus replication (Strating et al., 2015). Although we cannot exclude a role for the 
dichlorobenzyl or the dioxolane ring moiety, our data indicate that the extensive core structure of 
ITZ consisting of the four linked rings is key to inhibition of OSBP and thereby the antiviral 
activity of ITZ. 
 
Molecular modeling studies 
We previously showed that ITZ binds OSBP directly and inhibits its lipid shuttling function, 
most likely by targeting the ORD (Strating et al., 2015). In order to investigate the presumed 
binding of ITZ to the ORD of OSBP, a series of molecular modeling studies were conducted. 
Currently, no structural data are available for the ORD of human OSBP or OSBP-related proteins 
(ORPs). Therefore, we decided to build a homology model for the OSBP ORD based on the 
crystal structure of the yeast ORP Osh4/Kes1p (32% identity), which essentially consists of an 
ORD only (Im et al., 2005). We also considered the structure of the yeast ORP Osh3, but this 
protein only binds PI(4)P and the binding site is too narrow to accommodate sterols. Like OSBP, 
Osh4 mediates an exchange of sterols for PI(4)P (de Saint-Jean et al., 2011). The structure of 
Osh4 has been resolved in complex with different sterols, with PI(4)P and in the apo form (de 
Saint-Jean et al., 2011; Im et al., 2005). The Osh4 ORD contains a hydrophobic tunnel that can 
accommodate sterols or one of the two fatty acyl chains of PI(4)P. Sterol binding in this tunnel 
induces a conformational change that shifts an amino terminal helical lid in front of the tunnel 
entrance (Supplementary Figure 1A). The “closed” conformation is stabilized by interactions 
between the lid and the sterol (Im et al., 2005). We assumed that ITZ binds in the hydrophobic 
tunnel of OSBP, similar to how sterols bind to ORPs. In support of our assumption that ITZ can 
bind in a sterol-binding pocket, ITZ has also been shown to bind NPC1 in the sterol-binding 
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pocket (Head et al., 2017). Based on the Osh4p structures, we reasoned that ITZ should bind to 
the apo form of OSBP, since ITZ would have a steric clash with the lid in the closed, sterol-
binding conformation. Hence, the apo form of Osh4 was selected as a template to build a 
homology model of OSBP as detailed in the methods section (Supplementary Figure 1C). 
We then performed molecular docking studies of ITZ into the sterol-binding pocket of OSBP. 
According to our models, the sec-butyl chain of ITZ most likely inserts deep into the 
hydrophobic part of the sterol-binding tunnel leaving the dioxolane ring with the triazole and 
dichlorobenzyl moieties outside the pocket in a more solvent exposed area. Two possible 
orientations were found for this part of ITZ, in one of which this part of ITZ binds proximal to 
the strictly conserved OSBP “fingerprint motif” EQVSHHPP, to which the head group of PI(4)P 
normally binds (Tong et al., 2013) (Figure 3A). Importantly, as the hydrophobic pocket is too 
narrow to accommodate both ITZ and lipids (sterols or one of the legs of PI(4)P), it is very likely 
that ITZ competitively inhibits the lipid shuttling activity of OSBP. 
Importantly, the model is in agreement with the biological data obtained with the ITZ analogs. 
The triazole ring, positioned outside the tunnel in a solvent-exposed area, does not make specific 
interaction with the ORD, which is in accordance with the experimental data that the triazole ring 
is not important to drive accumulation of OSBP at the Golgi. We observed that the sec-butyl 
chain is fundamental for OSBP inhibition and only substitutions by bulky, non-linear side chains 
are tolerated. Based on our model, we conclude that a bulkier side chain better fills the narrow 
binding pocket at the bottom of the hydrophobic tunnel, whereas a linear alkyl chain has more 
flexibility in the tunnel and hence binds less tightly (Figure 3B). Finally, analogs that lacked part 
of the core structure of ITZ were inactive towards OSBP. In our model, the full length of the ITZ 
core is needed to bridge the distance between the pocket at the bottom of the hydrophobic tunnel 
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in which the sec-butyl chain docks and the outside of the tunnel where there is sufficient space to 
accommodate the bulky triazole-dichlorophenyl-dioxolane moiety. Shorter compounds would 
only fill part of the tunnel and would have significantly fewer hydrophobic interactions to 
stabilize them in the tunnel. 
13 
 
Discussion  
In this study, we explored the structural features of ITZ that are important for the OSBP-mediated 
antiviral activity through a structure-activity relationship study and a computational model of 
OSBP with ITZ. All the eight ITZ stereoisomers possess inhibitory activity towards OSBP and 
virus replication, which is consistent with the molecular models, which predict a fairly loose fit 
of ITZ in the sterol-binding pocket, providing sufficient space for any of the stereoisomers. Such 
a loose fit is also in accordance with the strength of the interaction that we previously measured 
(Kd = ~400 nM) (Strating et al., 2015), which implies a relatively weak interaction. Nevertheless, 
we did observe that the clinically used stereoisomers were a little more potent than the non-
clinically used isomers. 
We observed that the triazole moiety is not important for the OSBP-mediated antiviral activity. 
Since the triazole moiety is essential for the antifungal activity of ITZ (Odds et al., 2003), 
derivatives without the triazole moiety may have potential for antiviral therapy without CYP51- 
or CYP3A4-mediated adverse effects or the risk of inducing resistance against triazole-class 
antifungals in case a patient would have a fungal co-infection. Our data clearly show the 
importance of the sec-butyl chain for OSBP-mediated antiviral activity. However, some structural 
variations are tolerated, as long as the side chain is branched and relatively large. Finally, the full-
length core structure of ITZ appears important for the antiviral effect of ITZ to allow sufficient 
interactions with the hydrophobic tunnel.  
Besides a broad antiviral activity, ITZ possesses a potent anticancer activity against a number of 
different cancer types (Aftab et al., 2011; Antonarakis et al., 2013; Rudin et al., 2013; Tsubamoto 
et al., 2017). So far, only the molecular targets through which ITZ inhibits the mTOR (VDAC1, 
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NPC-1) signaling pathway have been identified (Head et al., 2015; Head et al., 2017; Kim et al., 
2010; Liang et al., 2017; Trinh et al., 2017; Tsubamoto et al., 2017). The target through which 
ITZ affects the trafficking, glycosylation and functioning of VEGFR2 has remained unknown. A 
number of ITZ analogs that we tested here, i.e. the stereoisomers and sec-butyl chain analogs, 
have previously been investigated for their effect on VEGFR2 glycosylation (which results from 
an inhibition of VEGFR2 trafficking and which correlates with impaired VEGFR2 functioning) 
and Hh signaling (as assayed using a reporter under control of the Hh-regulated transcription 
factor Gli1) (Shi et al., 2011). Only the sec-butyl chain analogs have been tested for Hh inhibition, 
which did not correlate with altered VEGFR2 glycosylation (Shi et al., 2011) and also does not 
correlate with OSBP-mediated antiviral activity (Table 3), which fits our previous conclusion that 
the antiviral activity of ITZ is unrelated to Hh inhibition (Strating et al., 2015). In general, our 
data suggest a correlation between the OSBP-mediated antiviral activity on the one hand and 
activity of ITZ analogs towards VEGFR2 glycosylation on the other hand (Tables 1 and 3). The 
sec-butyl chain analogs that were active towards OSBP and virus replication were also active 
towards VEGFR2 glycosylation (Table 3). The clinically used stereoisomers had a somewhat 
higher antiviral activity and affected VEGFR2 glycosylation more severely than the non-
clinically used stereoisomers (Table 1) (Shi et al., 2011; Shim  et al., 2016b). Only for the 
stereoisomers 2S4S2’R (compound 1f) and 2R4R2’R (compound 1h) the OSBP-mediated 
antiviral activity does not correlate with the previously reported effect on VEGFR2 glycosylation. 
At present, it is not clear whether this is truly due to different activities of those stereoisomers 
towards OSBP and VEGFR2 glycosylation, or whether the apparent discrepancy is caused by 
experimental differences (e.g. inhibitor concentrations, treatment times, cell lines, qualitative 
read-outs). Since we previously concluded that VEGFR2 glycosylation defect is likely unrelated 
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to the antiviral activity of ITZ (Strating et al., 2015), one possible explanation of our data is that 
inhibition of OSBP underlies the VEGFR2 glycosylation defects induced by ITZ, although future 
mechanistic studies (e.g. OSBP knock-down or testing additional ITZ analogs) are needed to 
corroborate this potential link. 
If indeed ITZ affects VEGFR2 via OSBP, the trafficking, glycosylation and functioning defects 
of VEGFR2 may well result from disturbances of cholesterol homeostasis caused by OSBP 
inhibition. Such a dependence of VEGFR2 on OSBP could be directly related to the sterol 
shuttling activity of OSBP but may also be an indirect effect through proteins that depend on 
OSBP-mediated lipid homeostasis. Namely, by modulating PI(4)P levels at the Golgi, OSBP is 
an important regulator of the ER-Golgi MCS (Mesmin et al., 2013) and as such of other lipid 
transfer proteins that operate at the ER-Golgi MCS. For example, the activity of the ceramide 
transfer protein CERT, which shuttles ceramide to the Golgi to allow the biosynthesis of 
sphingomyelin, is sensitive to OSBP inhibitors (Perry and Ridgway, 2006). Presumably, by 
perturbing the lipid composition of the Golgi apparatus, ITZ affects the overall functioning of the 
Golgi, which could explain the ITZ-induced changes in VEGFR2 trafficking, glycosylation and 
functioning. 
Together, our work contributes to the development of ITZ-derived antiviral compounds with an 
increased specificity towards OSBP and fewer side effects. Although it may not be possible to 
fully uncouple all activities of ITZ, it appears that at least OSBP-mediated antiviral activity can 
be uncoupled from antifungal activity (by removing or replacing the triazole group) and Hh 
inhibition (by altering the sec-butyl chain). Our computational model may facilitate medicinal 
chemistry optimization of ITZ because it allows to predict whether newly designed analogs can 
fit the hydrophobic pocket and thus exclude inactive analogs on forehand. 
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Experimental Section 
 
Chemistry 
ITZ has three chiral centers (designated 2, 4, 2’) (Figure 1). The synthesis of all eight ITZ 
stereoisomers and of sec-butyl chain analogs (compounds 5-8) has been previously described 
(Shi et al., 2011). The synthesis of the triazole deleted analog (compound 2) was previously 
described in (Chong et al., 2007; Head et al., 2015; Shi et al., 2011; Shi et al., 2010). Compound 
9 was synthesized as described in (Shi et al., 2010), and compound 11 was previously described 
in (Chong et al., 2007). The experimental procedure and characterization of compounds 3, 4 and 
10 are described in detail in the Supplementary methods.  
 
Cell Culture  
HeLa R19 cells were grown at 37°C, 5 % CO2 in Dulbecco’s modified Eagle’s medium (DMEM, 
Lonza) supplemented with 10 % fetal bovine serum. 
 
Infection Assays 
RLuc-EMCV, a recombinant virus encoding a Renilla luciferase gene upstream of the capsid-
coding region, was described before (Albulescu et al., 2015; Strating et al., 2015). Virus 
infections were performed by incubating subconfluent HeLa R19 cells with virus at MOI 0.1 at 
37°C for 30 min. Next, the medium was removed and fresh compound-containing medium was 
added to the cells. After 7h the medium was discarded and cells were lyzed to determine the 
Renilla luciferase activity using the Renilla luciferase Assay System (Promega) according to the 
manufacturer’s protocol. Cell viability was determined in parallel using the AQueous One 
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Solution Cell Proliferation Assay (Promega) according to the manufacturer’s protocol. The 
optical density at 490 nm was determined using a microplate reader.  
 
Fluorescence Microscopy 
Subconfluent HeLa R19 cells grown on coverslips in 24-well plates were transfected with 200ng 
per well of the pEGFP-hOSBP plasmid (Strating et al., 2015) using Fugene 6 (Promega) 
according to the manufacturer’s instruction. After overnight expression, the medium was 
discarded and fresh medium containing 10μM compound was added. After 1h the cells were 
fixed with 4 % PFA, permeabilized with 0.1 % Triton-X100, and the nucleus was stained with 
DAPI as previously described (Strating et al., 2015). Cells were embedded in FluorSave (Merck 
Millipore) and imaged using an Olympus BX60 fluorescence microscope. 
 
Molecular Modeling 
All molecular modeling studies were performed on a Viglen Genie Intel®CoreTM i7-3770 vPro 
CPU@ 3.40 GHz x 8 running Ubuntu 14.04. Molecular Operating Environment (MOE) 2015.10 
and Maestro (Schrödinger Release 2016-1) were used as molecular modeling software. 
The homology model of the OSBP ORD was prepared with the MOE2015.10 homology tool 
using a single template approach following a procedure previously reported (Bassetto et al., 
2016). The crystal structure of the ORD of Osh4p from Saccharomyces cerevisiae (PDB ID: 
1ZI7) in the apo form was used as template having a sequence similarity of 32% with the human 
isoform (Im et al., 2005). The amino acid sequence of human OSBP was loaded in MOE together 
with the 3D structure of the yeast isoform and manually aligned following the reported structure-
based alignment of ORDs (Tong et al., 2013), and the final 3D model was obtained as Cartesian 
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average of 10 generated intermediate models (Im et al., 2005). The new model was energy 
minimized using the Amber99 force filed and then validated in terms of the stereochemical 
quality of the backbone, side chain and amino acid environment using the online UCLA-DOE 
LAB web server. The structure of 7-hydroxycholesterol as it was co-crystallized with the ORD of 
Osh4 (PDB ID: 1ZHG) was inserted in the sterol-binding site of the OSBP ORD model after the 
superposition of the model and the crystal structure. 
The new model of the ORD of human OSBP was preprocessed using the Schrödinger Protein 
Preparation Wizard by assigning bond orders, adding hydrogen atoms and performing a 
restrained energy minimization of the added hydrogen atoms using the OPLS_2005 force field. A 
ligands database in sdf format was prepared using MOE2015.10 and then processed using the 
Maestro LigPrep tool by energy minimizing the structures (OPLS_2005 force filed), generating 
possible ionization states at pH 7±2, generating tautomers and low-energy ring conformers. A 20 
Å docking grid was prepared using as centroid the area occupied by 7-hydroxycholestrol. 
Molecular docking of the prepared ligands was performed using Glide standard precision (SP) 
keeping the default parameters and setting 5 as number of output poses per input ligand to 
include in the solution. The docking solutions were visual inspected in MOE2015.10 to identify 
the potential interaction between ligand and protein. 
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Figure legends 
 
 
 
 
 
Figure 1. Structure of ITZ. 
ITZ has three stereogenic centers (2, 4 and 2’), giving rise to eight different stereoisomers. The 
boxes indicate the side-chains that are changed in the tested analogs. 
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Figure 2. The effects of ITZ analogs on virus replication and OSBP redistribution. 
(A) HeLa R19 cells were infected with a Renilla luciferase (RLuc)-EMCV reporter virus, 
treated with compounds, and luciferase activity was determined as a quantitative measure 
of replication. Shown are ITZ as a positive control, and one representative example each 
of an active (compound 2) and an inactive (compound 9) analog. (B) In parallel, 
uninfected cells were treated with compound and cell viability was determined using an 
MTS assay. Experiments in (A) and (B) were performed as biological triplicates and 
mean values ± SEM are shown. (C) Up to four independent technical replicates (each 
performed as biological triplicates) were performed and EC50 values were calculated for 
each replicate (Supplementary Table 1) (except compounds 1c, 1e and 1g). Mean EC50 
values and SD are plotted and analyzed by one-way ANOVA with Bonferroni’s post hoc 
test. Asterisks indicate statistically significant differences compared to ITZ (**, p<0.01; 
***, p<0.001). Bars without asterisks are statistically not significantly different from ITZ. 
(D) HeLa R19 cells were transfected with a plasmid encoding EGFP-OSBP and treated 
for 1h with 10 μM compound. Cells were fixed, counterstained with DAPI to visualize 
the nuclei (blue) and imaged for OSBP localization using fluorescence microscopy. Only 
compounds that inhibit virus replication induce OSBP accumulation (see also Tables 1-4). 
Representative examples of independent technical replicates are shown. Scale bars 
correspond to 50 μm. 
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Figure 3. Modeling of the OSBP ORD structure with ITZ. 
(A) Homology model of the OSBP ORD in the open conformation. The sec-butyl chain of ITZ 
inserts deep in the hydrophobic tunnel, leaving the triazole-dichlorophenyl-dioxolane region 
outside in a more solvent exposed area. Our models calculated two possible orientations for 
this part (the two different models for ITZ are shown as yellow and light green carbon atoms 
respectively), one of which is in proximity of the strictly conserved “OSBP fingerprint motif” 
EQVSHHPP (lilac surface). The position of 7-hydroxycholesterol is shown in purple. (B) 
Zoom into the binding pocket of ITZ, only one calculated orientation of ITZ is shown. 
 
 
 
Tables 
 
Table 1. The activity of ITZ stereoisomers 
 
Means and standard deviations are from at least four independent technical replicates (except 
1c, 1e and 1g, which were tested twice), each performed as biological triplicates. 
a
 Stereoisomers included in clinically administered ITZ. 
b
 Data from Shi et al., 2011. 
c
 Inhibition of Hh signaling, determined using a reporter for the Hh-regulated transcription 
factor Gli1 (Shi et al., 2011). 
n.d.; not determined. 
 
Compound 
Inhibition of 
virus replication 
EC50 ± SD 
(µM) 
OSBP 
redistribution 
(10 μM) 
VEGFR2 
glycosylationb 
(2 μM)  
Hh inhibitionc 
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ITZ 0,46 ± (0,14) + ++ ++ 
1a 
(2S4R2’S)a 0,46 ± (0,08) + ++ n.d. 
1b 
(2S4R2’R)a 0,46 ± (0,12) + ++ n.d. 
1c 
(2R4S2’S)a 0,37 ± (0,06) + ++ n.d. 
1d 
(2R4S2’R)a 0,86 ± (0,22) + ++ n.d. 
1e 
(2S4S2’S) 2,63 ± (0,99) + + n.d. 
1f 
(2S4S2’R) 2,01 ± (0,38) + - n.d. 
1g 
(2R4R2’S) 3,21 ± (1,61) + + n.d. 
1h 
(2R4R2’R) 2,95 ± (1,26) + - n.d. 
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Table 2. The activity of ITZ triazole-moiety analogs 
 
Means and standard deviations are from at least four independent technical replicates, each 
performed as biological triplicates. 
a
 Data from (Shi et al., 2011). 
b
 Inhibition of Hh signaling, determined using a reporter for the Hh-regulated transcription 
factor Gli1 Shi et al., 2011. 
n.d.; not determined. 
 
Compound R1 
Inhibition of virus 
replication 
EC50 ± SD (µM) 
OSBP 
redistribution 
(10 μM) 
VEGFR2 
glycosylationa 
(2 μM) 
Hh 
inhibitionb  
ITZ 
  
0,46 ± (0,14) + ++ ++ 
2 
  
0,82 ± (0,22) + n.d. n.d. 
3 
 
 
0,43 ± (0,04) + n.d. n.d. 
4 
  
0,26 ± (0,16) + n.d. n.d. 
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Table 3. The activity of ITZ sec-butyl chain analogs 
 
Means and standard deviations are from at least four independent technical replicates, each 
performed as biological triplicates. 
a
 Data from (Shi et al., 2011). 
b
 Inhibition of Hh signaling, determined using a reporter for the Hh-regulated transcription 
factor Gli1 (Shi et al., 2011). 
 
 
 
Compound R2 
Inhibition of 
virus replication 
EC50 ± SD 
(µM) 
OSBP 
redistribution  
(10 μM) 
VEGFR2 
glycosylation  
(2 μM)a 
Hh 
inhibition
b
 
ITZ 
  
0,46 ± (0,14) + ++ ++ 
5 
  
> 10 - - ++ 
6 
  
> 10 - - - 
7 
  
0,25 ± (0,07) + ++ ++ 
8 
  
0,16 ± (0,12) + ++ - 
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Table 4. The activity of ITZ analogs with changes in the core structure 
 
Means and standard deviations are from at least three independent technical replicates, each 
performed as biological triplicates. 
a
 Compounds with changes in R3 
b
 Compounds with changes in R4 
c
 Data for ITZ from (Shi et al., 2011), data for Terconazole from (Nacev et al., 2011). 
d
 Inhibition of Hh signaling, determined using a reporter for the Hh-regulated transcription 
factor Gli1 (Shi et al., 2011). 
n.d.; not determined. 
 
Compound R3 / R4 
Inhibition of virus 
replication 
EC50 ± SD (µM) 
OSBP 
redistribution  
(10 μM) 
VEGFR2 
glycosylation  
(2 μM)c 
Hh 
inhibitiond 
ITZ 
 
0,46 ± (0,14) + + ++ 
Terconazole
a 
 
> 10 - - n.d. 
9a 
 
> 10 - n.d. n.d. 
10a 
 
> 10 - n.d. n.d. 
11b 
 
> 10 - n.d. n.d. 
  
 
